News
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...
Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...
Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...
4d
Zacks.com on MSNIs Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...
Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.
5d
Stocktwits on MSNNovo Nordisk Seeks Approval For Higher Wegovy Dose In EuropeStocktwits - Danish pharmaceutical company Novo Nordisk (CSE: NOVOb) (NVO) on Tuesday said that it has submitted an ...
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results